Self-Powered Microfluidic Device for Rapid Assay of Antiplatelet Drugs

We report the development of a microfluidic device for the rapid assay in whole blood of interfacial platelet-protein interactions indicative of the efficacy of antiplatelet drugs, for example, aspirin and Plavix, two of the world's most widely used drugs, in patients with cardiovascular diseas...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Langmuir : the ACS journal of surfaces and colloids. - 1999. - 32(2016), 11 vom: 22. März, Seite 2820-8
1. Verfasser: Jose, Bincy (VerfasserIn)
Weitere Verfasser: McCluskey, Peter, Gilmartin, Niamh, Somers, Martin, Kenny, Dermot, Ricco, Antonio J, Kent, Nigel J, Basabe-Desmonts, Lourdes
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2016
Zugriff auf das übergeordnete Werk:Langmuir : the ACS journal of surfaces and colloids
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Antibodies, Monoclonal Dimethylpolysiloxanes Immunoglobulin Fab Fragments Platelet Aggregation Inhibitors Platelet Glycoprotein GPIIb-IIIa Complex Powders Purinergic P2Y Receptor Antagonists Serum Albumin, Bovine mehr... 27432CM55Q Adenosine Monophosphate 415SHH325A baysilon 63148-62-9 cangrelor 6AQ1Y404U7 Fibrinogen 9001-32-5 Clopidogrel A74586SNO7 Prasugrel Hydrochloride G89JQ59I13 Ticagrelor GLH0314RVC Adenosine K72T3FS567 Ticlopidine OM90ZUW7M1 Abciximab X85G7936GV
LEADER 01000naa a22002652 4500
001 NLM257797858
003 DE-627
005 20231224183617.0
007 cr uuu---uuuuu
008 231224s2016 xx |||||o 00| ||eng c
024 7 |a 10.1021/acs.langmuir.5b03540  |2 doi 
028 5 2 |a pubmed24n0859.xml 
035 |a (DE-627)NLM257797858 
035 |a (NLM)26910300 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Jose, Bincy  |e verfasserin  |4 aut 
245 1 0 |a Self-Powered Microfluidic Device for Rapid Assay of Antiplatelet Drugs 
264 1 |c 2016 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 03.01.2017 
500 |a Date Revised 02.12.2018 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a We report the development of a microfluidic device for the rapid assay in whole blood of interfacial platelet-protein interactions indicative of the efficacy of antiplatelet drugs, for example, aspirin and Plavix, two of the world's most widely used drugs, in patients with cardiovascular disease (CVD). Because platelet adhesion to surface-confined protein matrices is an interfacial phenomenon modulated by fluid shear rates at the blood/protein interface, and because such binding is a better indicator of platelet function than platelet self-aggregation, we designed, fabricated, and characterized the performance of a family of disposable, self-powered microfluidic chips with well-defined flow and interfacial shear rates suitable for small blood volumes (≤200 μL). This work demonstrates that accurate quantification of cell adhesion to protein matrices, an important interfacial biological phenomenon, can be used as a powerful diagnostic tool in those with CVD, the world's leading cause of death. To enable such measurements, we developed a simple technique to fabricate single-use self-powered chips incorporating shear control (SpearChips). These parallel-plate flow devices integrate on-chip vacuum-driven blood flow, using a predegassed elastomer component to obviate active pumping, with microcontact-printed arrays of 6-μm-diameter fluorescently labeled fibrinogen dots on a cyclic olefin polymer base plate as a means to quantitatively count platelet-protein binding events. The use of SpearChips to assess in whole blood samples the effects of GPIIb/IIIa and P2Y12 inhibitors, two important classes of "antiplatelet" drugs, is reported 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a Antibodies, Monoclonal  |2 NLM 
650 7 |a Dimethylpolysiloxanes  |2 NLM 
650 7 |a Immunoglobulin Fab Fragments  |2 NLM 
650 7 |a Platelet Aggregation Inhibitors  |2 NLM 
650 7 |a Platelet Glycoprotein GPIIb-IIIa Complex  |2 NLM 
650 7 |a Powders  |2 NLM 
650 7 |a Purinergic P2Y Receptor Antagonists  |2 NLM 
650 7 |a Serum Albumin, Bovine  |2 NLM 
650 7 |a 27432CM55Q  |2 NLM 
650 7 |a Adenosine Monophosphate  |2 NLM 
650 7 |a 415SHH325A  |2 NLM 
650 7 |a baysilon  |2 NLM 
650 7 |a 63148-62-9  |2 NLM 
650 7 |a cangrelor  |2 NLM 
650 7 |a 6AQ1Y404U7  |2 NLM 
650 7 |a Fibrinogen  |2 NLM 
650 7 |a 9001-32-5  |2 NLM 
650 7 |a Clopidogrel  |2 NLM 
650 7 |a A74586SNO7  |2 NLM 
650 7 |a Prasugrel Hydrochloride  |2 NLM 
650 7 |a G89JQ59I13  |2 NLM 
650 7 |a Ticagrelor  |2 NLM 
650 7 |a GLH0314RVC  |2 NLM 
650 7 |a Adenosine  |2 NLM 
650 7 |a K72T3FS567  |2 NLM 
650 7 |a Ticlopidine  |2 NLM 
650 7 |a OM90ZUW7M1  |2 NLM 
650 7 |a Abciximab  |2 NLM 
650 7 |a X85G7936GV  |2 NLM 
700 1 |a McCluskey, Peter  |e verfasserin  |4 aut 
700 1 |a Gilmartin, Niamh  |e verfasserin  |4 aut 
700 1 |a Somers, Martin  |e verfasserin  |4 aut 
700 1 |a Kenny, Dermot  |e verfasserin  |4 aut 
700 1 |a Ricco, Antonio J  |e verfasserin  |4 aut 
700 1 |a Kent, Nigel J  |e verfasserin  |4 aut 
700 1 |a Basabe-Desmonts, Lourdes  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Langmuir : the ACS journal of surfaces and colloids  |d 1999  |g 32(2016), 11 vom: 22. März, Seite 2820-8  |w (DE-627)NLM098181009  |x 1520-5827  |7 nnns 
773 1 8 |g volume:32  |g year:2016  |g number:11  |g day:22  |g month:03  |g pages:2820-8 
856 4 0 |u http://dx.doi.org/10.1021/acs.langmuir.5b03540  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_22 
912 |a GBV_ILN_350 
912 |a GBV_ILN_721 
951 |a AR 
952 |d 32  |j 2016  |e 11  |b 22  |c 03  |h 2820-8